Another study, which included 53 lung cancer patients, indicated that the subjects who developed irAEs possessed lower baseline levels of CXCL9, CXCL10, CXCL11 and CXCL19, as well as a greater increase in CXCL9 and CXCL10 at post-treatment, compared with those without irAEs (148) (Figure 2). This evidence concerns the gene CXCL9 and lung carcinoma.